Cantor Fitzgerald Reiterates Overweight on Elevance Health, Maintains $547 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a price target of $547.
January 19, 2024 | 5:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Sarah James reaffirmed an Overweight rating on Elevance Health, with a price target of $547.
The reiteration of an Overweight rating and the maintenance of a high price target by a reputable analyst could lead to increased investor confidence in Elevance Health, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100